VivoSim Labs Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
FY EPS (est.)
-$0.89next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly26K
Annual Revenue Annually144K
Net Loss (Fiscal Year 2025) Annually-13.8M
Watch Items
- Going Concern UncertaintyTrigger: Auditor Rosenberg Rich Baker Berman & Company unqualified opinion expressing doubt on ability to continue as a going concernAction: Monitor cash burn, capital raises, and strategic partnerships to extend runway
- Preclinical IBD Program ProgressionTrigger: Transition of the novel drug candidate from medicinal chemistry to IND-enabling studiesAction: Track development milestones and potential licensing or co-development agreements
- Commercial Adoption of NAMkind ModelsTrigger: Accelerated adoption following the FDA's shift away from animal testing requirementsAction: Evaluate sales growth and new pharmaceutical/biotech partnerships for liver and intestinal toxicology services
Research as of 20 Jun 2026